GlassScriptPhysician profile
Cheryl E Kollman
NPI 1902828338
$14,173.08
in general payments reported to CMS, 2019-2025
59 companies · $3,350 in 2025
The $3,350 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,249 · 2022: $2,689 · 2023: $2,870 · 2024: $3,014 · 2025: $3,350.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,984 · Long Term Medical Supply Or Device Loan: $220 · Education: $31.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,984.14 |
| Long Term Medical Supply Or Device Loan | $219.96 |
| Education | $31.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $2,146.37 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Dexcom, INC. | $1,412.06 | 2021-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $923.08 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $891.68 | 2021-2025 | Evenity, Prolia, Tepezza |
| Abbott Laboratories | $829.47 | 2021-2025 | Freestyle Libre 3, Freestyle Copilot |
| Novo Nordisk INC | $782.13 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $460.49 | 2021-2025 | |
| Insulet Corporation | $432.95 | 2021-2025 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $407.03 | 2021-2025 | Jardiance |
| Corcept Therapeutics | $361.12 | 2021-2025 | Korlym |
| Antares Pharma, INC. | $324.92 | 2021-2025 | Xyosted, Tlando, Nocdurna |
| Sanofi-Aventis U.S. LLC | $316.28 | 2021-2025 | |
| Beta Bionics, INC. | $302.48 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Radius Health, INC. | $299.37 | 2021-2025 | Tymlos |
| Novartis Pharmaceuticals Corporation | $296.09 | 2021-2025 |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $260.56 | 2021-2025 | |
| Medtronic, INC. | $252.56 | 2021-2025 | Minimed 780g, Inceptiv |
| Abbvie INC. | $251.88 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $246.96 | 2024-2025 | |
| Amneal Pharmaceuticals LLC | $236.35 | 2021-2025 | Unithroid |
| Cequr Corporation | $228.17 | 2022-2025 | Cequr Simplicity |
| Almatica Pharma LLC | $185.61 | 2024-2025 | Teriparatide, Loreev Xr |
| Alexion Pharmaceuticals, INC. | $185.12 | 2021-2025 | Strensiq |
| Ibsa Pharma INC. | $185.04 | 2021-2024 | Tirosint, Licart, Tirosint |
| Mannkind Corporation | $159.73 | 2021-2022 | |
| Tandem Diabetes Care, INC. | $148.62 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Amarin Pharma, INC. | $144.07 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $126.34 | 2021-2024 | Cycloset |
| Endo USA, INC. | $98.15 | 2024-2025 | Aveed |
| Kowa Pharmaceuticals America, INC. | $91.47 | 2021-2024 | Livalo, Seglentis |
| Merck Sharp & Dohme LLC | $87.51 | 2021-2023 | Steglujan, Segluromet, Steglatro |
| Ascendis Pharma Endocrinology INC | $84.62 | 2025 | Yorvipath |
| Recordati_rare_diseases_inc. | $84.33 | 2021-2023 | Signifor Lar, Isturisa |
| Lifescan, INC. | $73.85 | 2021-2023 | |
| Kyowa Kirin, INC. | $73.12 | 2023-2025 | Crysvita |
| Endo Pharmaceuticals INC. | $65.45 | 2021-2024 | Aveed |
| Sequel Med Tech, LLC | $58.63 | 2025 | Twiist |
| Astrazeneca Pharmaceuticals LP | $53.09 | 2021-2024 | Farxiga |
| Eusa Pharma (US) LLC | $50.02 | 2022 | |
| Amryt Pharma Holdings LTD | $46.27 | 2022-2023 | Mycapssa |
| Tolmar, INC. | $44.61 | 2023-2025 | Jatenzo |
| Chiesi USA, INC. | $43.69 | 2024-2025 | Mycapssa |
| Zealand Pharma US, INC. | $42.99 | 2021-2022 | |
| Rhythm Pharmaceuticals, INC. | $39.58 | 2023-2025 | Imcivree, Imcivree |
| Madrigal Pharmaceuticals | $36.76 | 2025 | Rezdiffra |
| Halozyme INC | $35.66 | 2023 | |
| Averitas Pharma INC. | $32.51 | 2024-2025 | Qutenza |
| Esperion Therapeutics, INC. | $30.56 | 2021-2024 | Nexletol |
| Avvisto Therapeutics, LLC | $30.42 | 2025 | Cycloset |
| Becton, Dickinson and Company | $26.45 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $24.55 | 2024 | Crysvita |
| Acella Pharmaceuticals, LLC | $17.60 | 2025 | NP Thyroid 60 |
| Opko Pharmaceuticals, LLC | $17.19 | 2024 | Rayaldee |
| Eisai INC. | $16.74 | 2025 | |
| Rgh Enterprises LLC | $16.23 | 2025 | |
| Echosens North America, INC. | $14.10 | 2024 | Fibroscan |
| Ascensia Diabetes Care US INC. | $14.07 | 2024 | |
| Acerus Pharmaceuticals Corporation | $14.02 | 2021 | |
| Alfasigma USA, INC. | $12.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheryl Kollman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.